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1. INTRODUCTION 
 
1.1 Atrial Fibrillation Epidemiology 
Atrial fibrillation (AF) is the most prevalent and incident among the clinical 
arrhythmias1. Estimates of the prevalence of AF in the United States ranged from 
≈2.7 million to 6.1 million in 2010 and AF prevalence is estimated to rise to 12.1 
million in 2030. In the European Union, the prevalence of AF in adults >55 years of 
age was estimated to be 8.8 million (95% CI, 6.5–12.3 million) in 2010 and was 
projected to rise to 17.9 million in 2060 (95% CI, 13.6–23.7 million)1. 
 
Data retrieved from the Global Burden of Disease project showed that worldwide 
prevalence of AF is significant in Europe, North America and Australia, being higher 
in United States, as well as quite relevant in Russia [Figure 1]. Similar data can be 
found in relation to AF incidence [Figure 2]. Further, when the changes in prevalence 
and incidence are examined appears clear how, compared to 1990, significant 
increases for both indicators were found in the vast majority of world countries 
[Figure 3, Figure 4]. This evidence was also assessed in several specific report about 
AF epidemiology2,3. Furthermore, specific epidemiological data from developing 
countries showed that, even if on a lower magnitude, the increase in prevalence and 
incidence was significant even in these countries4. Taking together all the evidence 
available, it is possible to underline how we are facing a “growing global epidemic” for 
AF. 
 
Both prevalence and incidence have been found to progressively increase according 
to age and being higher in males than in females AF patients1,5. A higher incidence of 
AF was also described in White subjects, compared to other ethnicities1. 
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It has been also observed that AF is responsible of a relevant proportion of daily-
adjusted life years (DALYs)4, that was observed as significantly increasing in 2017 
compared to 1990 [Figure 5]. This increase in DALYs was also evident when 
examined according to male and female AF patients [Figure 6]. 
 
Lastly, risk of death attributable to AF was found to be increasing compared to 1990, 
both in male and female AF patients, in developed and developing countries4 [Figure 
7]. This data related to epidemiology of AF are paired with increased costs both at 
individual and population level, significantly affection health-care systems6. 
 
1.2 Relationship between Risk Factors and Incident AF 
The increasing incidence of AF in the worldwide scenario has been strictly 
associated with the increased prevalence of various cardiovascular and non-
cardiovascular risk factors7,8. Indeed, modifiable lifestyle risk factors as alcohol 
consumption, physical activity, psychological distress and smoking habit, as well as 
specific cardiovascular risk factors as hypertension, diabetes mellitus, obesity and 
obstructive sleep apnea syndrome have been significantly associated with the 
presence of new AF (Table 1). In particular for hypertension, diabetes mellitus and 
obesity a dose-response relationship was identified. This was also demonstrated by 
a recent systematic review9. 
 
The strict causal relationship between risk factor and incident AF, was also verified 
by the effectiveness of risk factor prevention strategies in terms of AF risk reduction. 
In the ARREST-AF study, an aggressive risk factors control management, aimed to 
control at the most all the major known cardiovascular risk factors10, reduced the risk 
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for AF recurrence in obese patients with at least 1 cardiovascular risk factor that 
underwent an ablation procedure11. This approach seems to suggest that to reduce 
at the most the risk of AF occurrence, a stricter risk factor control is needed, in order 
to combine all the beneficial effects of all the possible interventions. Extending this 
approach to the general population, we can hypothesize that interventions to obtain a 
strict risk factor control would be able to significantly reduce the overall risk of 
incident AF8 [Figure 8]. A modelling analysis in which the impact of various 
prevention strategies11,12 have been projected to the incidence rate of AF in a general 
population, showed how obtaining a progressively more strict control would grant to 
significantly reduce the rate of incident AF8. 
 
1.3 Thromboembolic Risk in AF Patients 
Ischemic stroke is the most common cardiovascular adverse event in AF patients, 
with an overall 5-fold increase in stroke risk and reported incidence of 19.5 per 1000 
patient-years in 200213. Additionally, stroke severity and recurrence risks are higher 
with AF.  
 
Evaluation of thromboembolic risk at baseline is a pivotal step in the management of 
thromboembolic risk in AF patients. The most largely used tool to evaluate this risk is 
the CHA2DS2-VASc score (Table 2)14. The almost universal adoption of CHA2DS2-
VASc score reflects the current data available, indicating it as the clinical risk score 
that provides better balance between evidence, practicality and precision15. A recent 
comparative effectiveness review about the ability of the scores to predict 
thromboembolic and bleeding events, reported that CHADS2, CHA2DS2-VASc and 
the recent ABC-Stroke16 scores all had similarly the best predictive capacity for 
stroke occurrence17. Nonetheless, CHA2DS2-VASc differs from other scores for its 
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capacity to effectively identify those patients with very low risk, also compared to 
ABC-Stroke it does not need to perform expensive and time-consuming laboratory 
tests to be drawn15. Furthermore, recently a systematic review and meta-regression 
demonstrated that CHA2DS2-VASc score represent the score with the highest 
probability to perform as the best in predicting occurrence of all-cause death in AF 
patients18. 
 
Oral anticoagulation (OAC) therapy with the vitamin K antagonists (VKA; e.g., 
warfarin), has been central for stroke prevention in the management AF. More 
recently, several drugs with direct inhibitory effects on thrombin and factor Xa have 
been developed19. These non-VKA oral anticoagulants (NOACs), namely, dabigatran 
etexilate, rivaroxaban, apixaban, and edoxaban, are proved to be as effective as 
warfarin for the prevention of stroke and systemic thromboembolism events in 
patients with AF20. All major guidelines recommend use of NOACs as well as well 
managed VKA for the prevention of stroke and thromboembolic risk in non-valvular 
AF patients19,21–23. However, OAC treatment is unavoidably associated with an 
increased risk of bleeding, regardless of OAC type used24,25. In patients treated with 
VKA, quality of anticoagulation control, as expressed as time in therapeutic range 
(TTR), is a major determinant of major adverse outcomes26–30, including stroke and 
major bleeding, hence interventions to obtain an optimal TTR control can be 
successful to optimize stroke prevention and minimize risk of bleeding events13. A 
TTR >70% is recommended to obtain an optimal control of anticoagulation 
treatment19. Conversely, in patients treated with NOACs, an optimal adherence to 
treatment is strongly needed to reduce the risk of stroke and major bleeding31. 
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1.4 Increased Risk of CV Death and All-Cause Death in AF 
In the last years, evidence raised about an increased risk of major adverse events, 
beyond the above-mentioned discussed risk of stroke, in particular cardiovascular 
(CV) death and all-cause death, even despite the use of OAC32–37. It emerges from 
several observational studies and secondary analyses of randomized controlled trials 
that patients with AF have a high risk of death, even higher than the risk of stroke.  
 
An analysis from an observational cohort in France showed how cumulative risk of 
death was progressively higher, even than the risk of stroke, over a long-term follow-
up observation with CV death being the main contributor36. A pooled analysis derived 
from Phase 3 trials about non-vitamin K antagonist oral anticoagulants in AF showed 
that stroke accounted only for less than 6% of deaths, with cardiac and other 
vascular related deaths accounting for more than 50% of events38. 
 
An analysis comparing two European observational cohorts enrolled 12 years each 
other apart documented that risk of CV death and all-cause death significantly 
increased over time, and is independently associated with increased age and several 
concomitant CV and non-CV comorbidities34. 
 
1.5 Role of Specific Comorbidities in AF Clinical History 
As described, several comorbidities have a significant impact in determining AF 
clinical history34. 
 
It is largely known that hypertension, defined as history of hypertension at the 
beginning of observation, is associated with an increased risk of adverse events in 
AF patients39,40. Indeed, hypertension is considered among CHA2DS2-VASc14 and 
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HAS-BLED41 risk scores as one of the main factors in predicting both 
thromboembolic and bleeding risk. A subgroup analysis from the ‘Apixaban for 
Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation’ 
(ARISTOTLE) trial found that clinical history of hypertension was associated with an 
increased risk of thromboembolic events (HR: 1.24, 95% CI: 1.03-1.49)42, while an 
analysis from the ‘Randomized Evaluation of Long-Term Anticoagulation Therapy’ 
(RE-LY) trial documented, conversely, an increased risk for major bleeding (HR: 
1.25, 95% CI: 1.06-1.46)43. In an analysis from the Atrial Fibrillation Follow-up 
Investigation of Rhythm Management (AFFIRM), blood pressure visit-to-visit 
variability was found to be associated independently associated with an increased 
risk for major adverse clinical outcomes, particularly stroke and major bleeding 
occurrence44. 
 
Also diabetes mellitus have been described as significantly associated to increased 
risk of major adverse outcomes in AF patients45,46. Some reports also described that 
duration of diabetes mellitus47, as well as glycaemic control48,49. 
 
In the recent years accumulating evidence suggest a strong relationship between AF 
and peripheral arterial disease (PAD)50–52. In particular, AF patients affected with 
PAD are found to be at increased risk of major adverse outcomes53. Since 2000, 
Frost and colleagues exploring the association between AF and incident stroke 
occurrence found that, despite a not particularly high prevalence, PAD was 
independently associated with stroke occurrence, both in male and female subjects 
(HR: 1.3, 95% CI: 1.0-1.7 and HR: 1.3, 95% CI: 1.0-1.6)54. A Follow-up analysis of 
the “Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: 
Collaborative Italian Study” (ARAPACIS) study further extended the evidence about 
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association between AF and PAD in determining adverse outcomes. Indeed, ABI 
≤0.90 was found significantly associated with incident MI (HR: 2.62, 95% CI: 1.32-
5.20), vascular death (HR: 2.24, 95% CI: 1.34-3.73) and the composite outcome of 
any vascular event (HR: 1.50, 95% CI: 1.11-2.03) over a 3 years follow-up time55. 
 
Recently, the role of chronic obstructive pulmonary disease (COPD) has been 
assessed in determining risk of adverse outcomes in AF patients. In a subgroup 
analysis from the EURObservational Research Programme in AF (EORP-AF) found 
that COPD was associated with higher rates of CV death, all-cause death and the 
composite outcome of any thromboembolic event/bleeding/CV death. Also, COPD 
was found independently associated with a higher risk of all-cause death56. Data 
coming from an observational study in a Chinese AF population reported that patients 
with both AF and COPD were at higher risk for both all-cause death (hazard ratio 
[HR]: 1.491) and CV death (HR: 1.595)57. A sub-group analysis from the ARISTOTLE 
study reported that COPD patients had a significant risk excess for both CV and all-
cause death, with a 40% to 60% relative risk increase58. Both studies reported no 
influence of COPD in determining stroke occurrence. A recent analysis from the 
‘Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K 
Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation’ 
(ROCKET AF) trial also showed that COPD confers an higher risk for both CV death 
(HR: 1.42) and all-cause death (HR: 1.65)37. 
 
Coronary artery disease (CAD) is also associated with worst outcomes in AF 
patients. A study from a large population-based cohort documented that presence of 
CAD was associated with an increased risk of stroke, myocardial infarction, CV death 
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and all-cause death. Also, the risk of events was proportionally higher according to 
the extent of CAD (1, 2 or 3 vessels)59. 
 
A recent paper derived from an observational cohort documented that also metabolic 
syndrome is associated with major adverse cardiac events (MACE), myocardial 
infarction, coronary revascularization and CV death. After a propensity matching 
adjustment metabolic syndrome conferred an independent risk for MACE (HR: 1.87, 
95% CI: 1.21–3.01), myocardial infarction (HR: 1.72, 95% CI: 1.54–5.00), coronary 
revascularization (HR: 2.18, 95% CI: 1.69–3.11), and CV death (HR: 2.27, 95% CI: 
1.14–5.11)60. 
 
Chronic kidney disease is an established risk factor for stroke, major bleeding, CV 
death and all-cause as it emerges from several studies61. The most striking issue in 
the relationship between chronic kidney disease and AF is the contemporary 
increased risk of stroke and major bleeding62. The Loire Valley Atrial Fibrillation 
Project showed that CKD, defined as an estimated glomerular filtration rate (eGFR) 
below 60 ml/min/1.73 m2, was associated with a higher incidence of ischemic 
stroke/thromboembolism events, but multivariable Cox regression analysis did not 
demonstrate an independent effect of renal impairment on predicting major adverse 
events, after adjusting for CHA2DS2-VASc score risk factors63,64. At the same time, in 
the same study the authors provided evidence for an increased risk of major 
bleeding. An analysis from the ‘Stroke Prevention Using Oral Thrombin Inhibitor in 
Atrial Fibrillation’ (SPORTIF) III and V studies, found that CKD was associated with 
risk of stroke, major bleeding and all-cause death65. The same study also underlined 
how the relationship between CKD and major adverse outcomes was strictly and 
significantly dependent on quality of anticoagulation control, as expressed by TTR65. 
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1.6 The Concept of Multimorbidity and AF 
The concept of multimorbidity (defined as the concomitant presence of two or more 
chronic conditions) has gained much medical attention in the last decades66. As with 
AF, the prevalence of multimorbidity increases with increasing age and is associated 
with a high risk of mortality, reduced functional status, increased healthcare 
expenditure and use of resources67. As part of the biological, sociological and clinical 
complexity associated with healthcare68, multimorbidity demands solid integrated 
care and an holistic approach to the patient in order to properly manage the 
associated risks67. Moreover, multimorbidity is very common in patients with CV 
disease69. 
 
The Charlson Comorbidity Index (CCI) has been validated as a reliable tool to 
evaluate the burden of multimorbidity in the general population and is significantly 
associated with an increased risk of all-cause death during the long-term follow-up70. 
Furthermore, CCI has been extensively validated in patients with CV disease71. 
Nevertheless, despite AF being associated with several comorbidities19, scarce data 
exist about the overall burden of multimorbidity, or the relationship with CCI, and AF. 
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2. OBJECTIVES OF THE DOCTORAL PROJECT 
 
2.1 General Objectives of Doctoral Project 
The general objectives of the project were to make a comprehensive report about 
prevalence of major cardiovascular and non-cardiovascular comorbidities among 
large AF patients cohorts derived from both contemporary randomized controlled 
trials (RCTs) and observational studies; further the project aimed to describe the 
interactions of clinical comorbidities with thromboembolic risk and antithrombotic 
therapy. Also, the project intended to report relationship between principal 
comorbidities and all-cause death occurrence. These initial general objectives of the 
study were achieved in the first part of the doctoral course and reported above, as 
part of the current available evidence regarding AF and its clinical history. Those 
objectives were achieved through multiple subgroup analysis, derived from several 
observational, randomized controlled trials and administrative databases. 
 
After the first part of the doctoral course was completed, the project moved to 
describe in more detail, among the role of single conditions and comorbidities, the 
burden of multimorbidity in AF in various specific scenarios. Further, the project 
aimed to describe the impact of multimorbidity in AF in determining OAC prescription, 
quality of OAC control, functional status, quality of life and major adverse outcomes. 
 
2.2 Specific Aims of the Thesis 
Moving from the general objectives of the doctoral project, this thesis will describe 
results derived from multiple analysis about the impact of multimorbidity on various 
health indexes and outcomes, derived from several different populations. 
More precisely, data from the following populations and studies will be reported: 
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• ‘Atrial Fibrillation Follow-up Investigation of Rhythm Management’ (AFFIRM) 
o The aims for this analysis were to analyse in a cohort derived from a 
randomised controlled trial the relationship between multimorbidity, 
expressed as the cumulative addition of the various comorbidities and TTR, 
quality of life and stroke, major bleeding, CV death and all-cause death. 
• ‘EURObservational Research Programme in Atrial Fibrillation’ (EORP-AF) 
General Pilot Study 
o The aims for this analysis were to analyse in a cohort derived from a 
multicentre observational European-wide study the relationship between 
multimorbidity, expressed as the cumulative addition of the various 
comorbidities, prescription of OAC and major adverse events, in particular 
CV death and all-cause death. 
• ‘REgistro POliterapie SIMI’ (REPOSI) Study 
o The aims for this analysis were to analyse in a cohort of hospitalised elderly 
(≥65 years old) patients the impact of multimorbidity, expressed as the 
Cumulative Illness Rating Scale Index of Comorbidity (CIRS-IC), in terms of 
functional status and its impact on CV death and all-cause death. 
• Lombardy Region Administrative Health Databases 
o The aims for this analysis were to retrospectively analyse in a population-
based cohort the relationship between multimorbidity, expressed as CCI, and 
AF and its impact on OAC prescription and stroke, major bleeding and all-
cause death occurrence 
• ‘Fibrilacion Auricular: influencia del Nivel y Tipo de Anticoagulacion Sobre la 
Incidencia de Ictus y Accidentes hemorragico’ (FANTASIIA) Study 
o The aims for this analysis were to analyse in a multicentre observational 
nationwide cohort the impact of multimorbidity, expressed as baseline 
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calculated CCI, on TTR and stroke, major bleeding, CV death and all-cause 
death. 
 
Hence, on the basis of previous evidence, experimental data provided will be 
discussed and interpreted in order to give an overall picture of the impact of 
multimorbidity in the context of AF. Lastly, a proposal for an improved management 
of these patients, originated by the results provided, will be presented. 
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3. MATERIALS AND METHODS 
3.1 General Characteristics of the Studies and Analyses Performed 
In this section the general characteristics of the studies used to perform the analyses 
above described. The specific methods related to indexes and outcomes, where it 
does apply will be also provided. 
 
3.1.1 The AFFIRM Study 
The AFFIRM study was a nationwide multicentre open-label randomized controlled 
trial, held in US and Canada from 1995 to 2001 by the US National Institute of 
Health. The original study aimed to compare the rate and rhythm control 
management strategies in terms of risk of death prevention. A total of 4060 patients 
were enrolled, followed up for a mean (SD) time of 3.5 (1.3) years. Patients were 
assigned to rate or rhythm control at baseline and then managed according to 
physicians’ discretion in relation to the current evidence-based practice72. 
 
Multimorbidity was evaluated as the cumulative addition of the 12 conditions 
available from the study database. On the basis of the distribution of the total number 
of conditions that were reported for each patient, the cohort was divided into four 
quartiles. Quality of anticoagulation control was evaluated according to TTR, for 
those patients prescribed with OAC. In a reduced cohort of patients (795, 19.5%) 
physical and mental health were evaluated according to Short Form 36 Health 
Survey (SF-36) (https://www.rand.org/health/surveys_tools/mos/36-item-short-
form.html), quality of life was evaluated according to Ferrans & Powers Cardiac III 
Quality of Life Index (https://qli.org.uic.edu/index.htm). 
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First stroke, first major bleeding, CV death, all-cause death, first hospitalization and 
first CV hospitalization were the outcomes considered. 
 
3.1.2 The EORP-AF General Pilot Study 
The EORP-AF General Pilot Study was a prospective multi-national survey 
conducted by the European Society of Cardiology in 9 European countries (Belgium, 
Denmark, Netherlands, Norway, Poland, Romania, Greece, Italy, and Portugal)  to 
determine clinical features, treatment patterns and outcomes amongst patients with 
AF managed by cardiologists73. The study enrolled both in- and outpatients 
accessing to cardiology services (either hospital or office-based centres) with AF as a 
primary or secondary diagnosis. The qualifying AF event was recorded by a 12-lead 
ECG, 24 h ECG Holter or other electrocardiographic documentation and should have 
been occurred within the 12 months before the enrolment. From February 2012 to 
March 2013, a total of 3,119 AF patients were enrolled. Follow-up observation was 
extended up to 3 years. The present analysis considered the 2119 patients available 
for the 3 years follow-up analysis, with a final number of 1629 of patients included. 
 
Multimorbidity was evaluated as the cumulative addition of 12 conditions as retrieved 
from the original database. On the basis of the median number of comorbidities, the 
cohort was divided into ‘low multimorbidity’ and ‘high multimorbidity’ groups. 
 
Prescription of OAC was evaluated at baseline. Stroke, any thromboembolic event 
(TE), bleeding events, CV death, all-cause death, any AF rehospitalization, any CV 
rehospitalization were considered as outcomes. 
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3.1.3 The REPOSI Study 
The REPOSI study is a multicentre collaborative observational registry jointly held by 
the Italian Society of Internal Medicine (SIMI), the IRCCS Ca’ Granda Maggiore 
Policlinico Hospital Foundation and the IRCCS Mario Negri Institute of 
Pharmacological Research, is based upon the participation of a representative 
network of internal medicine and geriatric wards in Italy. Full details about register 
design and specific aims have been reported74. Briefly, REPOSI was held for three 
non-consecutive years (2008, 2010, 2012) and then annually from 2014 onwards. In 
each of these years, consecutive patients acutely admitted to the participating wards 
and being older than 65 years were enlisted in the register over a period of 4 weeks 
on a quarterly basis (i.e. February, June, September and December). All diagnoses 
made at hospital admission were coded according to the International Classification 
of Diseases – 9th Edition (ICD-9) system. Medication use at admission and discharge 
was assessed according to the Anatomic Therapeutic Chemical (ATC) Classification 
System. 
 
Multimorbidity was evaluated according to the CIRS-IC index, an established tool to 
evaluate multimorbidity in elderly patients75. All patients with a diagnosis of AF, with 
data about CIRS-IC and available follow-up data were included in this analysis. Out 
of the 7003 patients enrolled in the registry so far, a total of 1102 patients were 
considered for this analysis. The analysis was performed according to CIRS-IC 
tertiles. 
 
The Short Blessed Test (SBT) was used as a tool to evaluate cognitive functions76. 
The Geriatric Depression Scale (GDS) was considered as a tool to evaluate 
depression in the elderly77. Patient functional status was assessed with the Barthel 
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index78. CV death, all-cause death and rehospitalization were the outcomes 
considered. 
 
3.1.4 The Lombardy Region Administrative Health Databases 
This study used linkable administrative health databases of the Lombardy Region 
which include the demographic data of all residents and detailed information on 
hospital admissions and drug prescriptions. To date, with a population of more than 
10 million inhabitants, Lombardy is the largest Italian region, comprising highly 
populated urban areas, as well as industrial and rural ones. 
 
All databases are linked anonymously using unique encrypted patient codes, in 
accordance with the Italian privacy regulations. By virtue of a specific agreement 
between the Mario Negri Institute and the Lombardy Region, for the use of the 
anonymous administrative data derived from these databases it was not necessary to 
obtain approval from any ethics committee. Data were available for fifteen 
consecutive years, from 2000 to 2014. For any hospital admission, all discharge 
diagnoses have been coded according to International Classification of Disease 9th 
revision [ICD-9]. Moreover, the hospital discharge database records the date of 
hospital admission, date of discharge or death and procedures performed during 
admission. The drug prescription database contains the drug name and its 
Anatomical Therapeutic Chemical classification code, quantity and dispensation date 
after the discharge at home, but not during the index hospitalization. All data about 
subjects ≥40 years old (>6 million inhabitants) were available and included in this 
analysis.  
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Data from 2000 to 2001 were used to build the clinical history of patients and to 
calculate baseline CCI. Year 2002 was used as index year to evaluate AF diagnosis. 
All discharge diagnoses were searched for codes 427.31 and 427.32, and all 
subjects with these codes irrespective of position, were assigned to the group of 
patients with prevalent AF. A random sample of non-AF patients ten times greater 
than those with AF was taken as a control group. 
 
According to the diagnoses reported at discharge and coded as per ICD-9, all 
patients were evaluated for presence of concomitant conditions. In its original 
definition, CCI comprised 19 diagnosis to which different weights have been assigned 
and summed to obtain the final calculation of CCI70. For this study, the CCI was 
calculated according to a validated method applied to the administrative databases79. 
All AF patients were grouped according to CCI as patients with low multimorbidity 
(CCI 0-3) and a high multimorbidity (CCI ≥4).  
 
OAC prescription at beginning and end of observation was evaluated according to 
both continuous and categorical CCI. Stroke, major bleeding and all-cause death 
were considered as outcomes and evaluated according to time-dependent 
continuous CCI. 
 
3.1.5 The FANTASIIA Study 
The FANTASIIA registry is an observational, prospective, national and multicentre 
study of clinical and demographic characteristics of Spanish AF patients. In brief, the 
main objective was to assess the incidence of thromboembolic and bleeding events 
in an unselected population of patients with AF, specifically the type of oral 
anticoagulant (VKA or NOACs) used and quality of anticoagulation with VKAs. 
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Between June 2013 and March 2014, all outpatients with confirmed diagnosis of 
paroxysmal, persistent or permanent AF, were prospectively enrolled. All patients 
included in the registry had been receiving OAC (VKA or NOACs) for at least 6 
months before enrolment. A total of 2178 patients were enrolled and followed for 2 
years. At baseline each investigator directly calculated CCI for each patient. Study 
cohort was divided on the basis of CCI quartiles. 
 
Quality of anticoagulation was evaluated according to TTR. Stroke, major bleeding, 
CV death and all-cause death were considered as outcomes. 
 
3.2 Statistical Methods 
All continuous variables were expressed as mean (SD) or median (IQR) according to 
variables characteristics. Differences between groups were assessed according to t-
test or One-Way ANOVA, and Mann-Whitney U test or Kruskal-Wallis ANOVA test 
according to the type of variable and the number of groups considered. Categorical 
variables were expressed as counts and percentages. Differences between groups 
were assessed with chi-square test. 
 
Differences throughout follow-up points of continuous variable were evaluated 
according to repeated measures ANOVA F test. 
 
Differences in cumulative risk of studies outcomes between groups were evaluated 
according to Kaplan-Meier curves. All linear and logistic regression analyses were 
performed as univariate and multivariate adjusted analyses according to biological 
plausibility and scientific evidence. Similarly, Cox regression analyses were 
performed as univariate and multivariate adjusted analyses according to biological 
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plausibility and scientific evidence. A two-sided value of p ≤ 0.05 was considered 
statistically significant. All the analyses were performed with SPSS 25.0 (IBM, NY, 
USA), Stata 13.0 (Stata Corp LP, College Station, TX, USA) or SAS software 9.4 
(SAS Institute). 
 
4. RESULTS 
4.1 The AFFIRM Study 
4.1.1 General Characteristics of the Population 
All the 4060 patients originally enrolled entered the study. Distribution of the number 
of concomitant comorbidities are reported in Figure 9. Among them, 11.1% had no 
comorbidities, 33.4% had one comorbidity and 55.5% had 2 or more comorbidities. 
According to quartiles, 1809 patients were in Q1 (0-1 comorbidity), 1108 were in Q2 
(2 comorbidities), 615 were in Q3 (3 comorbidities) and 528 were in Q4 (≥4 
comorbidities) (Table 3). General characteristics according the four quartiles are 
reported in Table 3. No differences were noted in terms of age and sex distribution, 
while smoking habit was progressively more prevalent according to the increasing 
quartiles. Also, patients were more likely symptomatic with increasing quartiles. 
 
Polypharmacy (≥5 drugs assumed contemporarily) was progressively more prevalent 
from Q1 to Q4, as well as the use of aspirin and the use of warfarin as OAC 
treatment (Table 3). Median CHA2DS2-VASc was progressively higher in the four 
quartiles, as well as the proportion of patients with high thromboembolic risk 
(CHA2DS2-VASc≥2). Conversely, TTR was found to be progressively lower as the 
quartiles increased. 
 
  25 
4.1.2 Relationship between Multimorbidity and TTR 
A multivariable adjusted logistic regression analysis found that an inverse association 
between the increasing quartiles and the prevalence of TTR >70% was found (Table 
4). Conversely, a progressively stronger direct association between increasing 
comorbidities quartiles and TTR ≤65% (bad control) and TTR ≤60% (very bad 
control) was confirmed. Similar evidence was retrieved considering the number of 
comorbidities as a continuous variable (Table 4). 
 
4.1.3 Follow-Up Analysis 
During follow-up observation, a significant increasing rate of all the outcomes 
considered, except for stroke, across the quartiles (Table 5). 
 
Kaplan-Meier curves documented across the quartiles an increased cumulative risk 
of stroke (p=0.037) [Figure 10], major bleeding (p<0.001) [Figure 11], CV death 
(p<0.001) [Figure 12] and All-Cause death (p<0.001) [Figure 13]. Similar data were 
found for first hospitalization (chi-square: 181.027, p<0.001) and first CV 
hospitalization (chi-square: 73.122, p<0.001). 
 
Adjusted Cox regression analysis showed that while stroke was not independently 
predicted by the burden of comorbidities, the highest quartile was associated with 
major bleeding occurrence (compared to Q1, Q2: HR 1.16, 95% CI 0.79-1.70; Q3: 
HR 1.52, 95% CI 0.99-2.33; Q4: HR 1.99, 95% CI 1.31-3.04). A progressively higher 
risk across the quartiles was found for CV death occurrence (compared to Q1, Q2: 
HR 2.56, 95% CI 1.60-4.10; Q3: HR 3.49, 95% CI 2.13-5.71; Q4: HR 8.70, 95% CI 
5.60-13.54). It was also associated with an increased risk of all-cause death 
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(compared to Q1, Q2: HR 2.14, 95% CI 1.56-2.94; Q3: HR 2.47, 95% CI 1.75-3.50; 
Q4: HR 5.53, 95% CI 4.06-7.52). 
 
The progressively increasing burden of comorbidity was also found associated with 
first hospitalization (compared to Q1, Q2: HR 1.32, 95% CI 1.18-1.48; Q3: HR 1.47, 
95% CI 1.29-1.68; Q4: HR 1.95, 95% CI 1.70-2.24) and first CV hospitalization 
(compared to Q1, Q2: HR 1.32, 95% CI 1.14-1.53; Q3: HR 1.38, 95% CI 1.15-1.65; 
Q4: HR 2.04, 95% CI 1.71-2.43). 
 
4.1.4 Quality of Life Evaluation 
A pool of 795 patients also entered the quality of life substudy. The SF-36 physical 
health and SF-36 mental health scores and the Ferrans & Powers Cardiac III Quality 
of Life Index were examined at 6 pre-specified follow-up points. Given the low 
number of subjects, the cohort was divided into two groups: i) low comorbidity: 0-3 
comorbidities; ii) high comorbidity: ≥4 comorbidities. 
 
As reported in Figure 14, patients with high comorbidity (black solid line) had a 
steadily lower score for the SF-36 physical health score (F: 11.308, p=0.001) [Figure 
14, Upper Panel], while there was no difference in terms of the SF-36 mental health 
score (F: 1.234, p=0.269) [Figure 14, Middle Panel].  Further, patients with high 
comorbidity has a steadily lower score for the Cardiac III Quality of Life Index (F: 
7.374, p=0.008) [Figure 14, Lower Panel]. 
 
4.2 The EORP-AF General Pilot Study 
The original study enrolled 3119 patients. Of these 2119 (67.9%) qualified for the 3 
years follow-up analysis. All the patients that had complete data about all the 12 
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chronic comorbidities considered were included in this analysis, with a final cohort of 
1629 AF patients. 
 
4.2.1 General Characteristics of the Population 
Among the patients included, the median [IQR] number of comorbidities was 3 [2-5]. 
Only 47 (2.9%) had no comorbidities, 178 (10.9%) had only one comorbidity, while 
the remaining 86.2% had ≥2 comorbidities. According to median value, we defined 
the low multimorbidity (840, 51.6%) and the high multimorbidity (789, 48.4%) (Table 
6). Patients with high multimorbidity were older, more likely obese and with a more 
likely permanent AF. 
 
At baseline, both median [IQR] CHA2DS2-VASc and HAS-BLED were higher in 
patients with high multimorbidity. As well as the proportion of high thromboembolic 
risk (CHA2DS2-VASc≥2) and high bleeding risk (HAS-BLED≥3) (Table 6). 
 
Patients with high multimorbidity were more likely treated with antiplatelet drugs and 
aspirin. While there was no difference in terms of the overall OAC use, patients with 
high multimorbidity were more likely treated with VKA, while those with low 
multimorbidity were more treated with NOACs (Table 6). Looking at the patterns of 
antithrombotic drugs, patients with high multimorbidity were more likely treated with 
duel antithrombotic therapy (antiplatelet drugs plus OAC) (Table 6). At univariate 
logistic regression analysis, the presence of high multimorbidity was not associated 
to any difference in OAC prescription (OR: 1.13, 95% CI: 0.88-1.45), so no 
multivariate analysis was performed. 
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4.2.2 Follow-Up Analysis 
After a 3 years follow-up observation, patients with high multimorbidity had a higher 
rate of any TE, CV death, all-cause death and of the composite outcome of any 
TE/bleeding/CV death (Table 7). Also, while the rate of any AF rehospitalization was 
lower in patients with high multimorbidity, the rate of any CV rehospitalization was 
conversely higher in those patients (Table 7). 
 
An adjusted logistic regression analysis found that high multimorbidity was 
significantly associated with the risk of any TE (OR: 1.88, 95% CI: 1.09-3.25), CV 
death (OR: 2.48, 95% CI: 1.59-3.87), all-cause death (OR: 2.77, 95% CI: 2.08-3.69), 
any TE/bleeding/CV death (OR: 2.14, 95% CI: 1.56-2.92) and any CV 
rehospitalization (OR: 2.00, 95% CI: 1.54-2.61). Conversely high multimorbidity was 
inversely associated with any AF rehospitalization (OR: 0.66, 95% CI: 0.51-0.86). 
 
Kaplan-Meier curves were drafted for CV death [Figure 15] and all-cause death 
[Figure 16], with high multimorbidity showing a significantly higher cumulative risk for 
both events (both p<0.0001). 
 
Cox fully multivariate adjusted analysis confirmed that high multimorbidity was 
significantly independently associated with CV death (HR: 2.38, 95% CI: 1.52-3.73) 
and all-cause death (HR: 2.57, 95% CI: 1.93-3.42) occurrence. 
 
4.3 The REPOSI Study 
4.3.1 General Characteristics of the Population 
According to baseline CIRS-IC, the 1102 patients included in the cohort were divided 
in three tertiles: i) T1= 362 patients; ii) T2= 412 patients; iii) T3= 328 patients (Table 
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8). No differences in age and sex proportion were found. Progressively higher values 
of GDS and SBT according to the increasing tertiles were found; conversely Barthel 
index was progressively lower. An increasing prevalence of caregiver presence was 
found across the tertiles, as well as the smoking habit. Accordingly, several of the 
comorbidities considered at baseline were found progressively more prevalent across 
the tertiles (Table 8). Furthermore, an increasing rate of polypharmacy was found 
across the three groups. 
 
CHA₂DS₂-VASc score was progressively higher across the tertiles. No difference in 
terms of any antithrombotic therapy (Table 8). 
 
4.3.2 Cognitive and Functional Status 
According to the CIRS-IC tertiles [Figure 17] it was found a progressively higher rate 
of dementia according to SBT (p=0.002), as well as a higher rate of depression 
according to GDS (p=0.014). Furthermore, an increasing proportion of patients 
moderately and highly dependent according to Barthel index, was found across the 
tertiles (p<0.001). 
 
4.3.3 Follow-Up Analysis 
During follow-up a progressively higher rate of CV death (4.4% vs. 6.8% vs. 10.7%, 
p=0.006), all-cause death (10.5% vs. 16.3% vs. 24.1%, p<0.001) across the tertiles, 
while the rate of rehospitalization was higher in the T3 (23.8% vs. 18.0% in T1 and 
15.8% in T2, p=0.019).  A multivariate adjusted logistic regression analysis found an 
increasing direct association between increasing tertiles and risk of all-cause death 
(compared to T1, T2: OR 1.55, 95% CI 1.01-2.39 and T3: OR 2.61, 95% CI 1.70-
4.01), conversely only the highest tertile was found directly associated with risk of CV 
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death (compared to T1, T2: OR 1.48, 95% CI 0.78-2.79 and T3: OR 2.61, 95% CI 
1.70-4.01) and with risk of rehospitalization (compared to T1, T2: OR 0.88, 95% CI 
0.60-1.29 and T3: OR 1.45, 95% CI 1.00-2.11). 
 
Continuous CIRS-IC was directly associated with increased risk of CV death (OR: 
1.26, 95% CI: 1.12-1.41), all-cause death (OR: 1.26, 95% CI: 1.16-1.37) and 
rehospitalization (OR: 1.11, 95% CI: 1.03-1.20). 
 
4.4 The Lombardy Region Administrative Health Databases 
4.4.1 General Characteristics of the Population 
In 2002, a total of 24,040 AF patients were retrieved, as well as 240,400 non-AF 
patients. At baseline (Table 9), AF patients had a significantly higher mean (±SD) 
CCI than non-AF subjects (1.8±2.1 vs. 0.2±0.9, p<0.001). Patients with AF were 
significantly older and more likely male, and more likely affected by comorbidities 
compared to non-AF subjects. Accordingly, AF patients had a significantly higher 
mean CHA₂DS₂-VASc score compared to non-AF subjects. 
 
Within the overall AF patient cohort, 4295 patients (17.9%) had high multimorbidity 
(CCI ≥4), while 19,745 (82.1%) had low multimorbidity (CCI 0-3) (Table 9). Mean 
(±SD) CCI for the high multimorbidity group was 5.5±1.8, while for the low 
multimorbidity group, 1.1±1.1 (p<0.001). Patients with high multimorbidity were older 
and more likely male than those with low multimorbidity (both p<0.001). In patients 
with high multimorbidity all conditions considered were more prevalent, except for 
hypertension which was more prevalent in the low multimorbidity group (p<0.001). 
Patients with high multimorbidity had a higher thromboembolic risk than the low 
multimorbidity group. At baseline, patients with high multimorbidity were significantly 
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less prescribed with OAC than those with low multimorbidity (30.0% vs. 42.3%, 
p<0.001) (Table 9). 
 
4.4.2 Trends in CCI and Relationship with AF 
A mixed linear effect logistic model was compiled to analyse the relationship between 
AF and CCI. Overall, CCI progressively increased over time both in non-AF and AF 
patients, being increasingly and steadily higher in AF patients compared to non-AF 
ones (p<0.001) [Figure 18]. After adjustment for years of observation, age, sex and 
an interaction term between AF and years of observation, AF was associated with a 
progressively higher CCI (beta coefficient: 1.69, 95% confidence interval [CI]: 1.67-
1.70), F= 99943.8, p<0.001). Further, the interaction term between AF and years of 
observation was also independently associated to the progressively higher CCI 
(p<0.001). Subgroup analysis for age classes, showed that this relationship was 
consistently statistically significant for patients <65 years, 65-74 years and ≥75 years 
(all p<0.001). 
 
4.4.3 CCI and OAC Prescription 
After adjustment for age and sex, CCI as a continuous variable was inversely 
associated with OAC prescription (odds ratio [OR]: 0.91, 95% CI: 0.89-0.92). The 
high multimorbidity category (CCI ≥4) was inversely associated with OAC 
prescription (OR: 0.65, 95% CI: 0.60-0.70).  
 
At the end of follow-up, even though CCI as a continuous variable was inversely 
associated with OAC prescription (OR: 0.98, 95% CI: 0.98-0.99), the high 
multimorbidity category was not significantly associated (OR: 0.98, 95% CI: 0.93-
1.04). Examining separately VKA and NOACs prescription, while there was no 
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difference in VKA prescription, both continuous (OR: 0.86, 95% CI: 0.81-0.90) and 
categorical (OR: 0.48, 95% CI: 0.37-0.63) CCI were inversely associated with 
prescription of NOACs. 
 
4.4.4 Survival and Regression Analysis 
At follow-up, all the outcomes showed higher cumulative incidence in the high 
multimorbidity group (all p<0.001). Kaplan-Meier analysis shows that risk for stroke, 
major bleeding and all-cause death was consistently higher in high multimorbidity 
group compared to the low multimorbidity group [Figure 19]. 
 
Cox regression analysis, using CCI as a continuous time-dependent variable to take 
account of the temporal increase and adjusted for age, sex and use of OAC, CCI was 
significantly associated with an increased risk for stroke (HR: 1.04, 95% CI: 1.02-1.06 
per increasing point), major bleeding (HR: 1.03, 95% CI: 1.01-1.06 per increasing 
point) and all-cause death (HR: 1.10, 95% CI: 1.09-1.11 per increasing point). 
 
4.5 The FANTASIIA Study 
4.5.1 General Characteristics of the Population 
According to availability of baseline CCI, among 2178 patients enrolled 1956 (89.8%) 
were available for the analysis. According to CCI patients were divided in quartiles: i) 
Q1= 676 patients; ii) Q2= 683 patients; iii) Q3= 345 patients; iv) Q4= 252 patients 
(Table 10). At baseline, a progressively lower proportion of female AF patients were 
found across the quartiles, with patients in Q3 and Q4 being more likely on 
permanent AF. Both CHA₂DS₂-VASc and HAS-BLED scores were progressively 
higher across the quartiles (both p<0.001) (Table 10). No differences were found in 
terms of OAC used, while antiplatelet drugs were progressively more prescribe 
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across the quartiles (Table 10). 
 
Mean (±SD) TTR was progressively lower according to increasing quartiles 
(63.1±24.5 vs. 62.0±25.3 vs. 62.2±25.7 vs. 54.7±24.2, p<0.001). Multivariate 
adjusted linear regression analysis found that CCI Q4 was inversely associated with 
TTR (unstandardized beta: -6.97, 95% CI: -11.59 / -2.36). Also, proportion of patients 
with TTR >70% was progressively lower from Q1 to Q4 (43.4% vs. 42.3% vs, 41.8% 
vs. 30.2%, p=0.010). Logistic regression analysis confirmed that only Q4 was 
inversely associated to TTR >70% (compared to Q1, Q2: OR 1.01, 95% CI 0.78-1.31, 
Q3: OR 1.02, 95% CI 0.74-1.41, Q4: OR 0.64, 95% CI 0.43-0.94). 
 
4.5.2 Follow-Up Analysis 
During the 2 years follow-up (Table 11) while no difference was found in terms of 
stroke rate (p=0.104), an increasing rate for major bleeding (p=0.003), CV death 
(p<0.001) and all-cause death (p<0.001) was found. Kaplan-Meier curves showed a 
progressively lower survival probability for major bleeding, CV death and all-cause 
death (all p<0.001) [Figure 20]. 
 
Multivariate adjusted Cox regression found a direct association for Q4 with risk of 
major bleeding and CV death, while an increasing direct association with risk of all-
cause death was found across the quartiles (compared to Q1, Q2: HR 1.52, 95% CI 
1.05-2.20, Q3: HR 1.91, 95% CI 1.25-2.89, Q4: HR 2.30, 95% CI 1.47-3.61) (Table 
11). A direct association in risk of major bleeding, CV death and all-cause death was 
found for continuous CCI (Table 11). 
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5. DISCUSSION 
5.1 General Overview of Results 
Data coming from the studies’ results above described, provided evidence the in AF 
patients, burden of multimorbidity has a direct impact on OAC prescription, quality of 
anticoagulation control, performance status, quality of life and, more importantly, on 
major adverse outcomes. Indeed, increasing multimorbidity were found inversely 
associated with OAC prescription, as well as with TTR. Further, in two of the studies 
reported, a higher multimorbidity were found to be characterized by an increased rate 
of depression, dementia and dependency in daily activities and by an impaired 
physical health and quality of life. Taking together all the evidence provided it was 
found that an increased burden of multimorbidity is directly associated with all the 
major adverse outcomes described (stroke, any TE, major bleeding, CV death, all-
cause death, rehospitalization). Finally, it was also provided evidence of a direct 
relationship between AF and progressively increasing burden of multimorbidity, 
independent by other context variables. 
 
5.2 Study Results in the Context of Current Knowledge 
The independent relationship between various single diseases and AF has been 
largely demonstrated. Indeed, as described above in the introduction several 
conditions contribute independently to incident AF occurrence and it has been 
suggested that tight control of concomitant risk factors and comorbidities could 
significantly reduce the burden of AF7,80. Furthermore, several diseases are 
independently prevalent in AF patients81,82. The data presented allow to establish a 
strong relationship and a direct link between AF and burden of multimorbidity, making 
AF as a proxy of a worse clinical status and a clinical model of multimorbidity. 
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The various designs of the studies presented, contributed to make evidence gathered 
solid. Obtaining data from randomized controlled trials, observational studies and 
population-based cohorts allowed us to acquire data that were both methodologically 
sound and representative of real life, both in general AF population and specific 
subgroup of elderly patients. Moreover, the use of validated tools to evaluate 
multimorbidity as CCI and CIRS-IC further reinforced the results. 
 
The influence of multimorbidity on OAC prescription, as we showed, represents a 
concerning trend, in particular if we consider the associated increased 
thromboembolic risk. In the study by Vanbeselaere and colleagues, there was a 
possible inverse relationship between increasing CCI and reduced OAC 
prescription83. This thesis extends previous knowledge, showing how this inverse 
relationship appears consistent in general AF population and over long-term 
observation periods. Moreover, we showed that if physicians appear to be more 
confident in prescribing VKA, the prescription of NOACs is significantly reduced in 
patients with increased multimorbidity. Our results substantiate previous observations 
that seem to suggest that AF patients prescribed with NOACs are relatively healthier 
and have less prevalent comorbidities81,84. 
 
Notwithstanding the strong results we described, so far data about AF and 
multimorbidity, in particular about validated tools as CCI or CIRS-IC have been 
scarce. In a Belgian study derived from a primary care registry, a modified version of 
the CCI was found higher in AF elderly (≥60 years) patients than in non-AF ones, 
also being associated with AF diagnosis83. The data presented in this thesis 
extended this previous evidence, confirming how the burden of multimorbidity is 
significant in AF patients, irrespective of age and of what may be the single medical 
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conditions. A recent study derived from the UK Biobank, in a cohort of patients with 
self-reported AF which examined the presence of multimorbidity as the additive 
presence of various conditions, only 19.6% of patients reported no comorbidities and 
11.1% of patients reported 4 or more comorbidities85. Very recently, a subgroup 
analysis derived from the ARISTOTLE study appeared to confirm the association 
between multimorbidity and all the relevant outcomes in AF patients86. 
 
In the recent years, the increased risk of CV-related and all-cause death in AF 
cohorts has shifted the main focus of prevention of adverse events from stroke to 
mortality33,36,37,87–89. Our data show that the increased and increasing multimorbidity 
burden is strongly associated with an increased risk of all the adverse events, stroke, 
major bleeding and all-cause death. The Framingham Heart Study previously 
showed that AF patients with comorbidities have a consistently increased risk for 
cardiovascular events and all-cause death compared to those without90. An analysis 
from the “Outcomes Registry for Better Informed Treatment of Atrial Fibrillation” study 
showed that when AF patients were clustered according to the more frequent clinical 
characteristics, those in the ‘low-comorbidity’ cluster had the lowest risk major 
cardiovascular and neurological adverse events than all the other identified clusters, 
variously affected by risk factors and other comorbidities82. 
 
This thesis also extends previous knowledge about the usefulness of CCI in AF 
patients. Thus far CCI have been already validated in patients with acute coronary 
syndrome91 and stroke92 and other cardiovascular conditions71. Hence this thesis 
provided solid and large evaluation of CCI in AF cohorts. 
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5.3 New Approaches to Manage Multimorbidity and Clinical Complexity 
On the basis of the showed increased burden of multimorbidity in AF patients, new 
approaches are required to manage these patients appropriately. In recent years 
there has been an increasing need of new approaches to manage AF patients, 
considering them in a more comprehensive, integrated and holistic way. A systematic 
review and meta-analysis by Gallagher and colleagues showed how an integrated 
care approach can significantly reduce hospitalization and mortality in AF patients93. 
Various expert opinions and international consensus statements have proposed new 
integrated models to properly manage AF patients, with the ultimate objective to 
reduce the risk of adverse events94,95. The “Atrial Fibrillation Better Care” pathway 
has recently been proposed as a possible model to integrate the various main 
aspects related to AF patients’ management, in order to streamline and facilitate the 
integrated care and the holistic evaluation of these patients96 and to be associated 
with a significant lower risk of major adverse events97. 
 
The strong association and relationship described between AF and multimorbidity 
requires the systematic adoption of a new approach that evaluate multimorbidity at 
baseline in all patients with AF. The recent ESC guidelines proposed a step-by-step 
approach in treating and managing new patients with AF19. On the basis of the 
results described, a modified version of this approach is proposed, taking ultimately 
account of the multimorbidity evaluation, to eventually identify a significant burden 
and adopt specific approaches to manage the associated risk, at the ABC pathway 
[Figure 21]. 
 
In the context of an increasing multimorbidity in the general population98, paired with 
the increasing costs associated with its presence and the claim to reduce the use of 
  38 
hospitalization and multiple referrals99, a more prominent role of specialist in internal 
medicine has been claimed to provide a patient-centred healthcare that would be 
able to manage patients with an holistic approach100. On this perspective, to face the 
burden of multimorbidity in AF patients, possibly a prominent role of specialist in 
internal medicine is due. Indeed, while heart team and cardiologist would provide 
specific care that would address the initial specialist management, specialist in 
internal medicine would be able to address all the aspects associated with clinical 
management of cardiovascular and non-cardiovascular comorbidities. 
 
Hence, on the basis of the multidisciplinary approach suggested by the 6th 
AFNET/EHRA Consensus Conference, a modified version is proposed, with the 
introduction of specialist in internal medicine in the Integrated AF Clinic. In this 
specific context, the specialist in internal medicine would be able to manage primary 
and secondary cardiac and vascular prevention, diabetes mellitus, COPD, chronic 
kidney disease and several other conditions usually part of the clinical skills of the 
specialist in internal medicine [Figure 22]. 
 
The proposal of integrating the internal medicine specialist in the clinical 
management of the patient with AF need to be intended as speculative and 
hypotheses generating. The evidence relating AF and multimorbidity appears to be 
solid and stemming from several studies with different designs. Notwithstanding to 
provide specific recommendations more data are still needed. Future studies that will 
specifically and prospectively address the evaluation of multimorbidity in AF, the 
impact of integrated management approaches and the role of the specialist in internal 
medicine will better elucidate the clinical utility of the approaches proposed. 
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6. CONCLUSIONS 
This thesis demonstrated that in AF patients exist a significant burden of 
multimorbidity, with a specific impact in determining treatments, performance and 
quality of life of patients. Also, and more importantly, the increased burden of 
multimorbidity is associated with an increased risk of all major adverse outcomes. In 
order to address this increased burden of multimorbidity, specific integrated 
management strategies to provide holistic treatment is needed. The assessment of 
multimorbidity would then be introduced in the systematic evaluation of AF patients. 
In the management of these patients a more prominent role of specialist in internal 
medicine, able to provide multiple skills to manage different conditions, is due to 
better implement the advocated integrated management. 
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TABLES 
Table 1: Association between main risk factors and risk of incident Atrial Fibrillation 
Clinical Factor Years Type of Studies Studies (N) Patients (N) Follow-
Up 
Increase in Risk* 
Modifiable Lifestyle Risk Factors 
Alcohol Consumption 1985-2014 Prospective Cohort 
Observational Cohort 
Case-Control 
17 245,903 2.5->50 
years 
HR 1.08 per 1 drink/day 
HR 1.08 per 10 g alcohol/day 
Physical Activity 2008-2015 Prospective Cohort 
Retrospective Cohort 
Longitudinal Cohort 
12 649,457 5.4-30 
years 
Leisure Exercise reduces risk 
Endurance Training increases risk 
Psychological Distress 2004-2012 Prospective 
Observational 
RCT 
5 83,442 7-10 
years 
Anger and Hostility: HR 1.1-1.3 
Tension: HR 1.28 
Anxiety: HR 1.16 
Panic Disorder: HR 1.73 
High Job Strain: HR 1.23 
Smoking Habit 1997-2015 Prospective Cohort 
Hospital Based 
Internet Based 
15 349,130 5-25.2 
years 
Former Smoker: HR 1.32-1.67 
Current Smoker: HR 1.44-2.05 
≤300 cig-years: HR 1.60 
>300 to ≤675 cig-years: HR 2.10 
Cardiovascular Risk Factors 
Diabetes Mellitus 1994-2014 Prospective Cohort 
Population Based 
RCT 
12 1,771551 3-38 
years 
HR 1.14 (NS) -1.40 
HR 1.13 per HbA1c 1% increase 
Higher risk was found for longer diabetes 
history 
HR 1.49 for incident diabetes 
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Hypertension 1994-2015 Prospective Cohort 
Community Based 
RCT 
9 76,475 2-38 
years 
SBP >140 mmHg progressively increases risk 
DBP >90 mmHg progressively increases risk 
HR 1.11-1.16 per 10 mmHg SBP increase 
HR 1.17 per 10 mmHg DBP increase 
Obesity 1996-2015 Prospective Cohort 
Community Based 
Population Based 
Case-Control 
10 152,122 4.7-34.3 
years 
Overweight: HR 1.18-1.22 
Obese: HR 1.40-1.65 
HR 1.45 per 5 kg/m2 increase 
OSAS 2007-2015 Prospective Cohort 2 10,383 4.7-11.9 
years 
HR 1.55-2.18 
Legend: Reproduced from Boriani and Proietti Heart 2017 doi:10.1136/heartjnl-2017-3115468; AF= Atrial Fibrillation; cig= cigarette; 
DBP= Diastolic Blood Pressure; HR= Hazard Ratio; NS= Not Significant; OSAS= Obstructive Sleep Apnoea Syndrome; SBP= 
Systolic Blood Pressure; RCT= Randomized Controlled Trials; *All HR reported are statistically significant, except where reported.
 Table 2: CHA2DS2-VASc Score 
 Score Item Scoring 
C Congestive Heart Failure 1 
H Hypertension 1 
A2 Age ≥75 Years Old 2 
D Diabetes Mellitus 1 
S2 Stroke or TIA 2 
V Vascular Disease 1 
A Age 65-74 Years Old 1 
Sc Sex Category (i.e. female) 1 
Legend: TIA= Transient Ischemic Attack. 
  
 Table 3: Baseline Characteristics according to Cumulative Comorbidities Quartiles in AFFIRM Study 
 Q1 
(0-1) 
N= 1809 
Q2 
(2) 
N= 1108 
Q3 
(3) 
N= 615 
Q4 
(≥4) 
N= 528 
p 
Age, years median [IQR] 71 [65-76] 70 [64-76] 71 [64-76] 71 [65-76] 0.078 
Female Sex, n (%) 731 (40.4) 450 (40.6) 229 (37.2) 184 (34.8) 0.065 
SBP, mmHg median [IQR] 131 [120-148] 135 [120-150] 132 [120-149] 120 [130-150] <0.001 
DBP, mmHg median [IQR] 78 [70-84] 78 [70-84] 76 [70-82] 72 [64-81] <0.001 
Smoking Habit, n (%) 156 (8.6) 146 (13.2) 94 (15.3) 100 (18.9) <0.001 
First AF Episode, n (%) 550 (31.6) 376 (35.1) 252 (42.4) 213 (41.8) <0.001 
Symptoms ≥2, n (%) 1048 (58.0) 687 (62.0) 423 (68.9) 404 (76.7) <0.001 
Randomized Treatment, n (%) 
Rate Control 
Rhythm Control 
 
895 (49.5) 
914 (50.5) 
 
563 (50.8) 
545 (49.2) 
 
305 (49.6) 
310 (50.4) 
 
264 (50.0) 
264 (50.0) 
0.914 
Drugs, n median [IQR] 3 [2-4] 4 [3-5] 5 [4-6] 6 [5-6] <0.001 
Polypharmacy, n (%) 425 (23.5) 457 (41.2) 345 (56.1) 400 (75.9) <0.001 
CHA2DS2-VASc, median [IQR] 2 [1-3] 3 [2-4] 4 [3-5] 5 [4-6] <0.001 
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CHA2DS2-VASc ≥2, n (%) 1295 (71.6) 1026 (92.6) 603 (98.0) 526 (99.6) <0.001 
Aspirin, n (%) 423 (23.4) 287 (25.9) 185 (30.1) 186 (35.2) <0.001 
Warfarin, n (%) 1508 (83.4) 935 (84.4) 530 (86.2) 461 (87.3) 0.097 
TTR, % median [IQR] 69.6 [55.7-81.9] 67.8 [50.3-81.4] 64.1 [46.1-80.0] 62.8 [44.3-77.8] <0.001 
Legend: AF= Atrial Fibrillation; BMI= Body Mass Index; DBP= Diastolic Blood Pressure; IQR= Interquartile Range; SBP= Systolic 
Blood Pressure; TTR= Time in Therapeutic Range. 
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Table 4: Logistic Regression Analysis for Quality of Anticoagulation Control Indexes 
 
TTR >70%* TTR ≤65%* TTR ≤60%* 
OR 95% CI p OR 95% CI p OR 95% CI p 
1st Quartile 
(ref.) 
2nd Quartile 
3rd Quartile 
4th Quartile 
- 
0.87 
0.73 
0.58 
- 
0.73-1.03 
0.59-0.90 
0.46-0.73 
- 
0.103 
0.004 
<0.001 
- 
1.22 
1.55 
1.76 
- 
1.03-1.45 
1.25-1.92 
1.39-2.22 
- 
0.023 
<0.001 
<0.001 
- 
1.34 
1.69 
1.91 
- 
1.12-1.60 
1.36-2.11 
1.51-2.42 
- 
0.001 
<0.001 
<0.001 
Cumulative 
Comorbidities 0.88 0.83-0.92 <0.001 1.16 1.09-1.22 <0.001 1.18 1.12-1.25 <0.001 
Legend: *Adjusted for age, sex, systolic blood pressure, diastolic blood pressure, first atrial fibrillation episode, randomized 
treatment and polypharmacy; CI= Confidence Interval; OR= Odds Ratio; TTR= Time in Therapeutic Range. 
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Table 5: Major Clinical Adverse Events according to Cumulative Comorbidities Quartiles 
 Q1 
(0-1) 
N= 1809 
Q2 
(2) 
N= 1108 
Q3 
(3) 
N= 615 
Q4 
(≥4) 
N= 528 
p 
Stroke, n (%) 57 (3.2) 45 (4.1) 31 (5.0) 24 (4.5) 0.136 
Major Bleeding, n (%) 92 (5.1) 66 (6.0) 46 (7.5) 53 (10.0) <0.001 
CV Death, n (%) 57 (3.2) 68 (6.1) 78 (12.7) 128 (24.2) <0.001 
All-Cause Death, n (%) 143 (7.9) 147 (13.3) 137 (22.3) 186 (35.2) <0.001 
First Hospitalization, n (%) 968 (54.4) 694 (63.5) 424 (69.9) 389 (76.7) <0.001 
First CV Hospitalization, n (%) 438 (30.3) 330 (37.1) 178 (38.8) 190 (50.5) <0.001 
Multiple Hospitalizations, n (%) 392 (27.1) 298 (33.5) 201 (43.8) 198 (52.7) <0.001 
Legend: CV= Cardiovascular 
 
 Table 6: Baseline Characteristics according to Comorbidity in EORP-AF Pilot 
Study 
 
 Low Multimorbidity 
N= 840 
High Multimorbidity 
N= 789 
p 
Demographics    
Age in years Median (IQR) 68.0 (61.0-75.0) 74.0 (66.0-80.0) <0.0001 
Female gender (%) 356 / 840 (42.4%) 306 / 789 (38.8%) 0.1395 
BMI, n (%)    
Underweight 9 / 799 (1.1%) 9 / 775 (1.2%) 0.0254 
Normal 245 / 799 (30.7%) 209 / 775 (27.0%)  
Overweight 345 / 799 (43.2%) 310 / 775 (40.0%)  
Obese 200 / 799 (25.0%) 247 / 775 (31.9%)  
Type of AF, n (%)    
First detected 281 / 840 (33.5%) 244 / 789 (30.9%) <0.0001 
Paroxysmal 235 / 840 (28.0%) 162 / 789 (20.5%)  
Long-standing persistent AF 185 / 840 (22.0%) 162 / 789 (20.5%)  
Persistent 27 / 840 (3.2%) 47 / 789 (6.0%)  
Permanent 112 / 840 (13.3%) 174 / 789 (22.1%)  
Current smoker, n (%) 95 / 818 (11.6%) 69 / 778 (8.9%) 0.0711 
Alcohol >= 2-3/day, n (%) 74 / 783 (9.5%) 58 / 751 (7.7%) 0.2277 
EHRA I Class, n (%) 369 / 840 (43.9%) 376 / 789 (47.7%) 0.1313 
Physical activity, n (%) 468 / 769 (60.9%) 388 / 751 (51.7%) 0.0003 
HAS-BLED score    
Median (IQR) 1.0 (0.0-2.0) 2.0 (1.0-3.0) <0.0001 
0-2 786 / 840 (93.6%) 583 / 789 (73.9%) <0.0001 
>=3 54 / 840 (6.4%) 206 / 789 (26.1%)  
CHA2DS2-VASc score    
Median (IQR) 2.0 (1.0-3.0) 4.0 (3.0-5.0) <0.0001 
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Legend: AF= Atrial Fibrillation; BMI= Body Mass Index; EHRA= European Heart 
Rhythm Association; NOACs= Non-Vitamin K Antagonist Oral Anticoagulants; OAC= 
Oral Anticoagulant; VKA= Vitamin K Antagonist. 
  
0 or 1 229 / 840 (27.3%) 12 / 789 (1.5%) <0.0001 
>=2 611 / 840 (72.7%) 777 / 789 (98.5%)  
Antithrombotic therapy, n (%)    
At least one 797 / 837 (95.2%) 762 / 789 (96.6%) 0.1689 
Any antiplatelet 231 / 838 (27.6%) 376 / 788 (47.7%) <0.0001 
Aspirin 212 / 838 (25.3%) 333 / 788 (42.3%) <0.0001 
Any OAC 666 / 834 (79.9%) 645 / 789 (81.7%) 0.3334 
VKA 600 / 834 (71.9%) 621 / 789 (78.7%) 0.0016 
NOACs 66 / 838 (7.9%) 26 / 789 (3.3%) <0.0001 
Patterns of Antithrombotic Drugs, 
n (%) 
   
No Antiplatelet/No OAC 40 / 834 (4.8%) 27 / 788 (3.4%) <0.0001 
Antiplatelet drugs only 128 / 834 (15.3%) 117 / 788 (14.8%)  
OAC only 566 / 834 (67.9%) 385 / 788 (48.9%)  
Antiplatelet + OAC 100 / 834 (12.0%) 259 / 788 (32.9%)  
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Table 7: Major Adverse Events at Follow-Up in EORP-AF Pilot 
 
Low 
Multimorbidity 
N= 840 
High 
Multimorbidity 
N= 789 p 
Stroke, n (%) 10 / 767 (1.3%) 13 / 619 (2.1%) 0.2486 
Any TE, n (%) 23 / 767 (3.0%) 34 / 619 (5.5%) 0.0201 
Bleeding, n (%) 24 / 766 (3.1%) 25 / 618 (4.0%) 0.3613 
CV Death, n (%) 30 / 840 (3.6%) 70 / 789 (8.9%) <0.0001 
All-Cause Death, n (%) 82 / 840 (9.8%) 183 / 789 (23.2%) <0.0001 
Any TE/Bleeding/CV death, n (%) 75 / 772 (9.7%) 123 / 653 (18.8%) <0.0001 
Any AF Rehospitalisation, n (%) 207 / 765 (27.1%) 119 / 620 (19.2%) 0.0006 
Any CV Rehospitalisation, n (%) 130 / 767 (16.9%) 179 / 619 (28.9%) <0.0001 
Legend: AF= Atrial Fibrillation; CV= Cardiovascular; TE= Thromboembolic Event. 
  
 Table 8: Baseline Characteristics according to the Burden of Comorbidity 
 Index of 
Comorbidity T1 
N= 362 
Index of 
Comorbidity T2 
N= 412 
Index of 
Comorbidity T3 
N= 328 
p 
Age years, median [IQR] 81 [76-86] 82 [77-86] 81 [76-86] 0.424 
BMI kg/m2, median [IQR] 660 24.7 [22.1-27.7] 25.7 [23.1-28.3] 25.6 [22.7-30.4] 0.323 
GDS, median [IQR] 628 1 [0-2] 1 [0-2] 1 [0-2] 0.010 
SBT, median [IQR] 677 6 [2-12] 8 [4-14] 10 [4-16] <0.001 
Barthel Index, median [IQR] 720 95 [82-100] 92 [68-100] 86 [62-100] <0.001 
Education years, median [IQR] 689 5 [5-10] 5 [5-10] 5 [5-8] 0.417 
Female Sex, n (%) 203 (56.1) 211 (51.2) 157 (47.9) 0.093 
Work Type, n (%) 
Low Income 
Middle Income 
High Income 
 
256 (76.0) 
49 (14.5) 
32 (9.5) 
 
312 (82.3) 
37 (9.8) 
30 (7.9) 
 
229 (77.9) 
34 (11.6) 
31 (10.5) 
0.221 
Marital Status, n (%) 
Single 
Married 
Unmarried 
 
182 (51.6) 
139 (39.4) 
32 (9.1) 
 
211 (52.9) 
164 (41.1) 
24 (6.0) 
 
164 (51.2) 
126 (39.4) 
30 (9.4) 
0.477 
Living Status, n (%)    0.374 
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Alone 
Spouse 
Family 
Institution 
90 (25.9) 
154 (44.3) 
78 (22.4) 
26 (7.5) 
89 (22.6) 
161 (40.9) 
107 (27.2) 
37 (9.4) 
64 (20.4) 
136 (43.5) 
79 (25.2) 
34 (10.9) 
Caregiver, n (%) 185 (51.2) 242 (59.2) 206 (63.6) 0.004 
Smoking Habit, n (%) 125 (35.6) 166 (40.9) 160 (50.3) 0.001 
Use of Alcohol, n (%) 142 (40.6) 180 (44.4) 152 (48.6) 0.118 
Hypertension, n (%) 270 (74.6) 352 (85.4) 302 (92.1) <0.001 
Hypercholesterolemia, n (%) 18 (5.0) 26 (6.3) 33 (10.1) 0.026 
Heart Failure, n (%) 102 (28.2) 124 (30.1) 117 (35.7) 0.089 
Coronary Artery Disease, n (%) 69 (19.1) 79 (19.2) 95 (29.0) 0.002 
Previous MI, n (%) 10 (2.8) 16 (3.9) 14 (4.3) 0.539 
Peripheral Arterial Disease, n (%) 6 (1.7) 13 (3.2) 17 (5.2) 0.033 
Previous Stroke/TIA, n (%) 30 (8.3) 40 (9.7) 39 (11.9) 0.282 
Diabetes Mellitus, n (%) 65 (18.0) 118 (28.6) 139 (42.4) <0.001 
CKD, n (%) 55 (15.2) 105 (25.5) 159 (48.5) <0.001 
COPD, n (%) 70 (19.3) 103 (25.0) 118 (36.0) <0.001 
Neoplasm, n (%) 23 (6.4) 46 (11.2) 57 (17.4) <0.001 
Polypharmacy, n (%) 247 (68.8) 314 (76.8) 291 (89.0) <0.001 
CHA2DS2-VASc, median [IQR] 4 [3-4] 4 [3-5] 4 [4-5] <0.001 
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Any Antiplatelet, n (%) 108 (29.8) 128 (31.1) 119 (36.3) 0.160 
VKA, n (%) 159 (43.9) 167 (40.5) 142 (43.3) 0.596 
Any NOAC, n (%) 21 (5.8) 30 (7.3) 18 (5.5) 0.550 
Any OAC, n (%) 180 (49.7) 197 (47.8) 160 (48.8) 0.869 
Legend: BMI= body mass index; CKD= chronic kidney disease; COPD= chronic obstructive pulmonary disease; GDS= geriatric 
depression scale; IQR= interquartile range; MI= myocardial infarction; OAC= oral anticoagulant; SBT= short blessed test; TIA= 
transient ischemic attack. 
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Table 9: Baseline Characteristics according to Atrial Fibrillation and Charlson Comorbidity Index 
 Non-AF 
N= 240400 
AF 
N= 24040 
p AF 
 
CCI 0-3 
N= 19745 
CCI ≥4 
N= 4295 
p 
Age, years mean±SD 59.7±13.2 76.1±9.8 <0.001 75.7±9.9 77.8±8.8 <0.001 
Age classes, n (%) 
 
<0.001   <0.001 
<65 years 155310 (64.6) 2964 (12.3) 
 
2651 (13.4) 313 (7.3)  
65-74 years 47525 (19.8) 6702 (27.9) 
 
5611 (28.4) 1091 (25.4)  
≥75 years 37565 (15.6) 14374 (59.8) 
 
11483 (58.2) 2891 (67.3)  
Male, n (%) 11096 (46.2) 12079 (50.2) <0.001 9841 (49.8) 2238 (52.1) <0.001 
Charlson Comorbidity Index, (mean±SD) 0.2±0.9 1.8±2.1 <0.001 1.1±1.1 5.5±1.8 <0.001 
Hypertension, n (%) 79801 (33.2) 18605 (77.4) <0.001 15452 (78.3) 3153 (73.4) <0.001 
Diabetes Mellitus, n (%) 4316 (1.8) 3555 (14.8) <0.001 1763 (8.9) 1792 (41.7) <0.001 
Myocardial Infarction, n (%) 1723 (0.7) 1400 (5.8) <0.001 869 (4.4) 531 (12.4) <0.001 
Congestive Heart Failure, n (%) 2919 (1.2) 7249 (30.1) <0.001 4882 (24.7) 2367 (55.1) <0.001 
Cerebrovascular Disease, n (%) 3216 (1.3) 3605 (15.0) <0.001 1625 (8.2) 1980 (46.1) <0.001 
Hemiplegia, n (%) 2282 (0.9) 2830 (11.8) <0.001 1027 (5.2) 1803 (42.0) <0.001 
Dementia, n (%) 489 (0.2) 400 (1.7) <0.001 197 (1.0) 203 (4.7) <0.001 
COPD, n (%) 3125 (1.3) 4017 (16.7) <0.001 2523 (12.8) 1494 (34.8) <0.001 
Connective Tissue Disease, n (%) 560 (0.2) 303 (1.3) <0.001 228 (1.1) 75 (1.7) 0.002 
Ulcer, n (%) 620 (0.3) 440 (1.8) <0.001 287 (1.4) 153 (3.6) <0.001 
Mild Liver Disease, n (%) 1918 (0.8) 1212 (5.0) <0.001 669 (3.4) 543 (12.6) <0.001 
Moderate/Severe Liver disease, n (%) 769 (0.3) 334 (1.4) <0.001 44 (0.2) 290 (6.7) <0.001 
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Legend: AF= Atrial Fibrillation; CCI= Charlson Comorbidity Index; COPD= Chronic Obstructive Pulmonary Disease; SD= Standard 
Deviation. 
 
  
Renal Disease, n (%) 1244 (0.5) 2087 (8.7) <0.001 788 (4.0) 1299 (30.24) <0.001 
Metastatic Tumor, n (%) 1162 (0.5) 503 (2.1) <0.001 0 (0.0) 503 (11.7) <0.001 
Leukemia, n (%) 117 (0.1) 86 (0.4) <0.001 49 (0.2) 37 (0.9) <0.001 
Lymphoma, n (%) 305 (0.1) 190 (0.8) <0.001 90 (0.5) 100 (2.3) <0.001 
Any Tumor, n (%) 4423 (1.8) 2189 (9.1) <0.001 1124 (5.7) 1065 (24.8) <0.001 
CHA₂DS₂-VASc, (mean±SD) 1.4±1.2 3.3±1.4 <0.001 3.2±1.3 4.1±1.5 <0.001 
Oral Anticoagulant Drugs, n (%) 4141 (1.7) 9646 (40.1) <0.001 8358 (42.3) 4295 (30.0) <0.001 
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Table 10: Baseline Characteristics according to Charlson Comorbidity Index Quartiles 
 Q1 
N= 676 
Q2 
N= 683 
Q3 
N= 345 
Q4 
N= 252 
p 
Age, years (mean±SD) 73.6±9.3 73.2±10.0 74.4±9.6 74.9±8.2 0.118 
Female, n (%) 356 (52.7) 293 (42.9) 131 (38.0) 80 (31.7) <0.001 
Type of AF, n (%) 
Paroxysmal 
Persistent 
Long-Term Persistent 
Permanent 
 
245 (36.2) 
125 (18.5) 
29 (4.3) 
277 (41.0) 
 
181 (26.5) 
125 (18.3) 
32 (4.7) 
345 (50.5) 
 
82 (23.8) 
44 (12.7) 
16 (4.6) 
203 (58.8) 
 
62 (24.6) 
34 (13.5) 
14 (5.6) 
142 (56.3) 
<0.001 
BMI, kg/m2 (mean±SD) 28.3±4.3 29.1±4.7 29.8±5.6 29.0±5.4 <0.001 
GFR, mL/min (mean±SD) 71.8±27.1 75.1±34.7 72.5±40.7 61.92±28.1 <0.001 
Smoking Habit, n (%) 34 (5.0) 35 (5.1) 17 (4.9) 13 (5.2) 0.999 
Excessive Alcohol, n (%) 11 (1.6) 34 (5.0) 15 (4.3) 12 (4.8) 0.006 
CHA2DS2-VASc (mean±SD) 2.8±1.1 3.7±1.4 4.5±1.5 5.1±1.6 <0.001 
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HAS-BLED (mean±SD) 1.7±0.9 1.9±1.0 2.3±1.0 2.7±1.2 <0.001 
OAC Drugs, n (%) 
VKA 
NOACs 
 
505 (74.7) 
171 (25.3) 
 
506 (74.1) 
177 (25.9) 
 
270 (78.3) 
75 (21.7) 
 
202 (80.2) 
50 (19.8) 
0.152 
Antiplatelet Drugs, n (%) 43 (6.4) 62 (9.1) 47 (13.6) 55 (21.8) <0.001 
Legend: AF= Atrial Fibrillation; BMI= Body Mass Index; GFR= Glomerular Filtration Rate; NOACs= Non-vitamin K Oral 
Anticoagulants; OAC= Oral Anticoagulant; SD= Standard Deviation; VKA= Vitamin K Antagonist. 
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Table 11: Major Adverse Events according to Charlson Comorbidity Index Quartiles 
 Q1 Q2 Q3 Q4 Continuous 
CCI 
p 
Stroke/TIA, n (%) 8 (1.2) 18 (2.6) 11 (3.2) 8 (3.2) - 0.104 
HR (95% CI)* Ref. 1.78 (0.75-4.22) 1.87 (0.68-5.08) 1.80 (0.59-5.53) 1.16 (0.88-1.52)  
Major Bleeding, n (%) 36 (5.3) 47 (6.9) 33 (9.6) 30 (11.9) - 0.003 
HR (95% CI)* Ref. 1.18 (0.75-1.86) 1.52 (0.90-2.56) 1.93 (1.10-3.40) 1.19 (1.02-1.38)  
CV Death, n (%) 14 (2.1) 36 (5.3) 27 (7.8) 30 (11.9) - <0.001 
HR (95% CI)* Ref. 1.78 (0.95-3.37) 1.98 (0.98-4.01) 2.72 (1.30-5.69) 1.32 (1.13-1.56)  
All-Cause Death, n (%) 45 (6.7) 86 (12.6) 65 (18.8) 59 (23.4) - <0.001 
HR (95% CI)* Ref. 1.52 (1.05-2.20) 1.91 (1.25-2.89) 2.30 (1.47-3.61) 1.26 (1.13-1.41)  
Legend: *Adjusted for type of AF and CHA2DS2-VASc score; CCI= Charlson Comorbidity Index; CV= Cardiovascular; TIA= 
Transient Ischemic Attack. 
  
 FIGURES 
Figure 1: Worldwide Prevalence of Atrial Fibrillation 
 
Legend: Data from Global Burden of Disease (http://www.healthdata.org/gbd). 
  
  72 
Figure 2: Worldwide Incidence of Atrial Fibrillation 
 
Legend: Data from Global Burden of Disease (http://www.healthdata.org/gbd). 
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Figure 3: Percental Changes in Worldwide Prevalence of Atrial Fibrillation 
 
Legend: Data from Global Burden of Disease (http://www.healthdata.org/gbd). 
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Figure 4: Percental Changes in Worldwide Incidence of Atrial Fibrillation 
 
Legend: Data from Global Burden of Disease (http://www.healthdata.org/gbd). 
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Figure 5: Annual Percental Changes in DALYs Related to Atrial Fibrillation 
 
Legend: DALYs= Daily-Adjusted Life Years; Data from Global Burden of Disease 
(http://www.healthdata.org/gbd). 
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Figure 6: Trends in Changes in DALYs Related to Atrial Fibrillation 
 
Legend: DALYs= Daily-Adjusted Life Years; Data from Global Burden of Disease 
(http://www.healthdata.org/gbd). 
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Figure 7: Mortality Attributable to Atrial Fibrillation 
 
Legend: Data from Global Burden of Disease (http://www.healthdata.org/gbd). 
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Figure 8: Effect of Various Interventions on Incident AF Occurrence 
 
Legend: Expected incidence of atrial fibrillation (AF) without any prevention strategy 
and implementing the suggested global management of risk factors. Details about 
risk factors control strategies can be found in Pathak et al for ARREST-AF and 
Huxley et al for ARIC11,12. 
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Figure 9: Distribution of Concomitant Comorbidities in the AFFIRM Study 
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Figure 10: Cumulative Risk of Stroke according to Comorbidities Quartiles in 
the AFFIRM Study 
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Figure 11: Cumulative Risk of Major Bleeding according to Comorbidities 
Quartiles in the AFFIRM Study 
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Figure 12: Cumulative Risk of CV Death according to Comorbidities Quartiles 
in the AFFIRM Study 
 
Legend: CV= Cardiovascular. 
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Figure 13: Cumulative Risk of All-Cause Death according to Comorbidities 
Quartiles in the AFFIRM Study 
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Figure 14: Quality of Life Evaluation in the AFFIRM Study 
 
Legend: Black Solid Line= High Comorbidity; Black Dashed Line= Low Comorbidity. 
  
  85 
Figure 15: Kaplan-Meier Curve for CV Death in EORP-AF Pilot 
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Figure 16: Kaplan-Meier Curve for All-Cause Death in EORP-AF Pilot 
 
 
 Figure 17: Performance Scales Categories according to the Burden of Comorbidity 
 
 
Legend: CIRS IC= Cumulative Illness Rating Scale Index of Comorbidity; GDS= Geriatric Depression Scale; SBT= Short Blessed 
Test.
 Figure 18: Charlson Comorbidity Index Trends according to Atrial Fibrillation 
Diagnosis across the Follow-Up 
 
Legend: Whiskers stand for standard deviation of mean; AF= Atrial Fibrillation; CCI= 
Charlson Comorbidity Index. 
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Figure 19: Kaplan-Meier Curves for Major Adverse Events according to 
Charlson Comorbidity Index Classes 
 
Legend: CCI= Charlson Comorbidity Index. 
  
 Figure 20: Kaplan-Meier Curves for Major Adverse Events according to Charlson Comorbidity Index Quartiles 
 
 Figure 21: A New Modified Approach to Treat and Manage AF Patients 
 
Legend: AF= Atrial Fibrillation, LV= Left Ventricular; adapted from Kirchhof et al. 201619. 
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Figure 22: An Alternative Model for the Integrated AF Clinic with Implementation of Specialist in Internal Medicine 
 
Legend: AF= Atrial Fibrillation; LAA= Left Atrial Appendage.  
